Alopexx
- Company typePublic
- Founded2021
- HeadquartersConcord, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Alopexx firmographics
Firmographics- Name
- Alopexx
- Legal name
- Alopexx, Inc.
- Website
- https://alopexx.com
- Company type
- Public
- Founded year
- 2021
- Operating status
- Ipo
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Alopexx industry classification
Industry- Product category
- Infectious Disease Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
- akta.pro secondary industries
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)
Keywords
Where Alopexx is headquartered
LocationHeadquarters
- HQ city
- Concord
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Alopexx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Distribution channels1 record
Marketing channels4 records
Alopexx product offering
Product offeringCore offering
Alopexx is a clinical-stage biotechnology company developing broad-spectrum immune therapeutics that target the conserved microbial surface polysaccharide poly-N-acetyl glucosamine (PNAG). Its two lead candidates are F598, a fully human monoclonal antibody providing immediate passive protection, and AV0328, a synthetic PNAG-conjugate vaccine delivering active immunity against bacterial, fungal, and parasitic infections including antimicrobial-resistant organisms.
Product overview
Alopexx is a clinical-stage biotechnology company with two distinct immune therapeutic products: a fully human monoclonal antibody (F598) and a synthetic conjugate vaccine (AV0328), both targeting the conserved PNAG antigen found on over 75 microbial pathogens. F598 provides immediate but time-limited passive protection (2-3 months) for acute settings like ICU patients, while AV0328 delivers long-term active immunity through vaccination. The PNAG Platform underlies both products and enables broad-spectrum coverage against bacterial, fungal, and parasitic infections including antibiotic-resistant organisms.
Differentiator
Problem solved
Functional benefit
Products and services
- F598 Monoclonal Antibody A fully human IgG1 monoclonal antibody targeting PNAG (poly-N-acetyl glucosamine) that mediates killing of PNAG-expressing microbial pathogens. It provides immediate passive protection for 2-3 months from a single infusion and is being developed for prevention of healthcare-associated infections in ICU patients.
- AV0328 Vaccine A synthetic PNAG-based conjugate vaccine designed to prevent infections caused by Streptococcus pneumoniae and other PNAG-expressing pathogens. Phase 1 first-in-man trial completed with demonstrated safety and broad-spectrum efficacy against over 10 microbial species, targeting serotypes and serogroups not covered by existing vaccines.
Quantifiable outcome
- Phase 1 trials completed for both F598 and AV0328 with no serious adverse events observed
- +3 more outcomes
Companies that use Alopexx
Customer profileSegments4 records
Ideal customer profiles3 records
Alopexx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Alopexx partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Bharat BiotechcoreCollaboration with Bharat Biotech for the development and commercialization of broad-spectrum anti-microbial vaccine AV0328. This partnership leverages Bharat Biotech's expertise in vaccine development and commercialization capabilities to advance AV0328 globally, particularly in regions where affordable broad-spectrum vaccines are needed.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
Alopexx competitors and assessment
Company assessmentDirect peers
- Moderna: Moderna is a direct peer as a platform-driven vaccine biotechnology company developing mRNA-based infectious disease vaccines. Both companies pursue platform-based approaches to broad anti-infective vaccination, targeting pathogens where conventional vaccines have fallen short, and both are clinical-stage with multiple infectious disease programs.
- BioNTech: BioNTech is a direct peer as a platform vaccine biotech that has built infectious disease vaccine programs on a novel antigen technology (mRNA). Both companies aim to displace narrow-spectrum traditional vaccines with broad, platform-based immune approaches.
- Novavax: Novavax is a direct peer as a vaccine platform biotech focused on recombinant protein nanoparticle vaccines for infectious diseases. Both companies develop novel vaccine technologies targeting infectious diseases where existing serotype- or strain-specific vaccines leave coverage gaps.
Emerging players
- Iterum Therapeutics: Iterum is an emerging peer developing anti-infective therapies for drug-resistant infections. While focused on small-molecule antibiotics rather than immune therapeutics, it competes in the same AMR market opportunity that Alopexx targets with F598 and AV0328.
- Cidara Therapeutics: Cidara is an emerging peer developing novel immunotherapies and antivirals for serious infectious diseases. Both companies are clinical-stage biotechs pursuing immune-mediated alternatives to traditional antibiotics for prevention and treatment of resistant infections.
- Arcturus Therapeutics: Arcturus is an emerging peer developing mRNA-based vaccines and therapeutics for infectious diseases. Both companies are clinical-stage platform biotechs pursuing next-generation vaccine approaches to address pathogens inadequately covered by current vaccines.
Broad incumbents
- Merck & Co. Merck is a broad incumbent in vaccines (Vaxneuvance pneumococcal, Gardasil) and anti-infectives. It competes with Alopexx in pneumococcal disease prevention and is a likely strategic acquirer or partner candidate for novel anti-infective platforms.
- GSK: GSK is a broad incumbent in vaccines with extensive pneumococcal, meningococcal, and global pediatric vaccine portfolios. AV0328 competes directly with GSK's serogroup and serotype-specific franchises, particularly in meningitis and pneumonia prevention.
- Sanofi: Sanofi is a broad incumbent with a leading vaccines franchise (Sanofi Pasteur) spanning influenza, pediatric combination vaccines, and emerging infectious disease targets. Sanofi is a natural strategic partner or acquirer for novel anti-infective platforms like Alopexx's.
- Pfizer: Pfizer is a broad incumbent in infectious disease vaccines, anchored by the Prevnar 13/20 pneumococcal franchise that AV0328 is positioned to complement or challenge. Pfizer is also Alopexx CBO Christine de los Reyes' former employer, illustrating the talent overlap in this space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Alopexx social profiles
Digital presenceAlopexx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alopexx leadership team
Management profileNumber of profiles
Profiles5 records
Alopexx funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alopexx M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alopexx
What does Alopexx do?
Alopexx is a clinical-stage biotechnology company developing broad-spectrum immune therapeutics that target the conserved microbial surface polysaccharide poly-N-acetyl glucosamine (PNAG). Its two lead candidates are F598, a fully human monoclonal antibody providing immediate passive protection, and AV0328, a synthetic PNAG-conjugate vaccine delivering active immunity against bacterial, fungal, and parasitic infections including antimicrobial-resistant organisms.
Is Alopexx a public or private company?
Alopexx is a public company. It is classified as public and is currently ipo.
When was Alopexx founded?
Alopexx was founded in 2021. It employs 11 to 50 people.
Where is Alopexx based?
Alopexx is headquartered in Concord, United States, in the North America region.
Who are Alopexx's main competitors?
Direct peers on record are Moderna, BioNTech and Novavax. Emerging players are Iterum Therapeutics, Cidara Therapeutics and Arcturus Therapeutics. Broad incumbents are Merck & Co., GSK, Sanofi and Pfizer.
Does Alopexx have an API?
No public API is recorded for Alopexx.
What industry is Alopexx in?
Alopexx's product category is Infectious Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 325414 and its SIC code is 2836.